Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral drugs Clear all
Completed Phase 1 Interventional Results available

Study of Novel Antiretrovirals in Participants With HIV-1

NCT05585307
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 14, 2026, 5:16 AM EDT
Terminated No phase listed Observational

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

NCT01474954
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Adherence, Improvement Measure (AIM) System

NCT01252212
View directory record Official record
Conditions
Patient Compliance, AIDS
Interventions
SMS medication adherence, No SMS adherence reminder
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 14, 2026, 5:16 AM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926
View directory record Official record
Conditions
HIV Infections
Interventions
Once daily
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Behavioral Intervention to Enhance HIV Test/Treat

NCT01752777
View directory record Official record
Conditions
HIV/AIDS
Interventions
Infectiousness Risk Reduction, General Health Improvement
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Effect of Interleukin-2 on HIV Treatment Interruption

NCT00015704
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 5:16 AM EDT
Completed No phase listed Observational

Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

NCT00179335
View directory record Official record
Conditions
HIV Infections
Interventions
Blood drawing to determine drug levels
Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 14, 2026, 5:16 AM EDT
Completed No phase listed Observational

Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I

NCT01253850
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Fenway Community Health
Other
Eligibility
13 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 14, 2026, 5:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents

NCT02134431
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
flexible sigmoidoscopy or colonoscopy with biopsies
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
10 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

NCT00002374
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 14, 2026, 5:16 AM EDT
Completed No phase listed Observational

Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)

NCT05152953
View directory record Official record
Conditions
Hiv
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Timeline
2022 – 2023
U.S. locations
4
States / cities
Auburn, Alabama • San Francisco, California • Fort Lauderdale, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

NCT00344461
View directory record Official record
Conditions
HIV
Interventions
Nevirapine, FTC, and Tenofovir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

NCT00086359
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

NCT05406583
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose), Dolutegravir 0.5 mg/kg liquid suspension (starts at 2-5 days of life)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

NCT00752856
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Isentress, Atripla
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

NCT01338883
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

MMF for HIV Reservoir Reduction

NCT03262441
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection
Interventions
Mycophenolate Mofetil 500Mg Tab
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828
View directory record Official record
Conditions
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
Interventions
cenicriviroc
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 14, 2026, 5:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Integrated HIV Prevention and HCV Care for PWID

NCT03981445
View directory record Official record
Conditions
HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions
ARTAS Adapted Patient Navigation, Adherence Counseling
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 64 Years
Enrollment
446 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 14, 2026, 5:16 AM EDT
Completed No phase listed Observational

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

NCT01886404
View directory record Official record
Conditions
HIV Infection
Interventions
Efavirenz
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders

NCT02128087
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Two-way SMS intervention, One-way SMS intervention group
Behavioral
Lead sponsor
RAND
Other
Eligibility
15 Years to 24 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 14, 2026, 5:16 AM EDT
Completed Not applicable Interventional

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

NCT00002168
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • Torrance, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 14, 2026, 5:16 AM EDT